2Blum J L,Jones S E,Buzdar A U,et al.Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J].J Clin Oncol,1999,17(2):485-493. 被引量：1
3Stewart D J,Evans W K,Shepherd F A,et al.Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer:superiority of doxorubicin[J].J Clin Oncol,1997,15(5):1897-1905. 被引量：1
4O'Shaughnessy J,Miles D,Vukelja S,et al.Superior survival with capeicitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer:phase Ⅲ trial results[J].J Clin Oncol,2002,20(12):2812-2823. 被引量：1
5Blum J L,Jones S E,Buzdar A U,et al.Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J].J Clin Oncol,1999,17(2):485-493. 被引量：1
6Verma S,Ilersich A L.Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer[J].Oncologist,2003,8 (3):232-240. 被引量：1
7Sawada N,Ishikawa T,Fukase Y,et al.Induction of thymidine phosphorylase activity and enhancement of capeicitabine efficacy by taxol/taxotere in human cancer xenografts[J].Clin Cancer Res,1998,4(4):1013-1019. 被引量：1
8Ishikawa T,Sekiguchi F,Fukase Y,et al.Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts[J].Cancer Res,1998,58(4):685-690. 被引量：1
9Budman D R,Meropol N J,Reigner B,et al.Preliminary studies of a novel fluoropyrimidine carbamate:capecitabine[J].J Clin Oncol,1998,16(5):1795-1802. 被引量：1
10Blum J L,Dieras V,Lo Russo P M,et al.Multicenter,phase Ⅱ study of capeicitabine in taxane-pretreated metastatic breast carcinoma[J].Cancer,2001,92(7):1759-1768. 被引量：1
9BLAGOSKLONNY M V,SCHULTE T, NGUYEN P,et al. Tax- ol induced apoptosis and phosphorylation of Bcl-2 protein in- volves c-Raf-1 and represents a novel c-Raf-1 signal transduc-tion pathway [ J]. Cancer Res, 1996,56 : 1851 - 1854. 被引量：1
